APHRODITE
Research type
Research Study
Full title
A Phase II trial of Higher RadiOtherapy Dose In The Eradication of early rectal cancer.
IRAS ID
250957
Contact name
Clare E Skinner
Contact email
Sponsor organisation
University of Leeds
Duration of Study in the UK
2 years, 11 months, 28 days
Research summary
An increasing number of patients with early rectal cancer in the UK are being identified through the bowel screening programme. There is a growing number of patients who may not be suitable for surgery, due to other medical comorbidities and factors. These patients may suffer from symptoms as their cancer grows, including pain, diarrhoea and the need for a stoma (bowel bag). For these patients, radiotherapy combined with chemotherapy, or radiotherapy only is used. A standard dose of radiotherapy given over 5.5 weeks can lead to the cancer disappearing in about one third of patients. In this trial we want to find out if a higher radiotherapy dose given over the same time will give greater benefit to patients with acceptable side effects. This could lead to better treatment and improved quality of life.
REC name
North West - Greater Manchester East Research Ethics Committee
REC reference
19/NW/0565
Date of REC Opinion
26 Sep 2019
REC opinion
Favourable Opinion